Metal Organic Frameworks as Drug Targeting Delivery Vehicles in the Treatment of Cancer

被引:118
|
作者
Cai, Mengru [1 ]
Chen, Gongsen [1 ]
Qin, Liuying [1 ]
Qu, Changhai [1 ]
Dong, Xiaoxv [1 ]
Ni, Jian [1 ,2 ]
Yin, Xingbin [1 ]
机构
[1] Beijing Univ Chinese Med, Sch Chinese Mat Med, Beijing 102488, Peoples R China
[2] Beijing Univ Chinese Med, Beijing Res Inst Chinese Med, Beijing 100029, Peoples R China
基金
中国国家自然科学基金; 北京市自然科学基金;
关键词
metal organic framework; targeting drug delivery system; nanoparticle; ONE-POT SYNTHESIS; PHOTODYNAMIC THERAPY; ANTICANCER DRUG; CONTROLLABLE SYNTHESIS; NANOPARTICLES; TUMOR; PH; SYSTEM; FABRICATION; RELEASE;
D O I
10.3390/pharmaceutics12030232
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In recent years, metal organic frameworks (MOFs) have been widely developed as vehicles for the effective delivery of drugs to tumor tissues. Due to the high loading capacity and excellent biocompatibility of MOFs, they provide an unprecedented opportunity for the treatment of cancer. However, drugs which are commonly used to treat cancer often cause side effects in normal tissue accumulation. Therefore, the strategy of drug targeting delivery based on MOFs has excellent research significance. Here, we introduce several intelligent targeted drug delivery systems based on MOFs and their characteristics as drug-loading systems, and the challenges of MOFs are discussed. This article covers the following types of MOFs: Isoreticular Metal Organic Frameworks (IRMOFs), Materials of Institute Lavoisier (MILs), Zeolitic Imidazolate Frameworks (ZIFs), University of Oslo (UiOs), and MOFs-based core-shell structures. Generally, MOFs can be reasonably controlled at the nanometer size to effectively achieve passive targeting. In addition, different ligands can be modified on MOFs for active or physicochemical targeting. On the one hand, the targeting strategy can improve the concentration of the drugs at the tumor site to improve the efficacy, on the other hand, it can avoid the release of the drugs in normal tissues to improve safety. Despite the challenges of clinical application of MOFs, MOFs have a number of advantages as a kind of smart delivery vehicle, which offer possibilities for clinical applications.
引用
收藏
页数:27
相关论文
共 50 条
  • [2] Nanoscale Metal Organic Frameworks for Drug Delivery
    Xinyi Lai
    Zhiyong Wang
    Yongtai Zheng
    Yongming Chen
    PROGRESS IN CHEMISTRY, 2019, 31 (06) : 783 - 790
  • [3] Anti-cancer Drug Delivery Using Metal Organic Frameworks (MOFs)
    Ibrahim, Mihad
    Sabouni, Rana
    Husseini, Ghaleb A.
    CURRENT MEDICINAL CHEMISTRY, 2017, 24 (02) : 193 - 214
  • [4] Metal organic frameworks in biomedicine: Innovations in drug delivery
    Benny, Alan
    Pai, Sunaja Devi Kalathiparambil Rajendra
    Pinheiro, Dephan
    Chundattu, Sony J.
    RESULTS IN CHEMISTRY, 2024, 7
  • [5] Metal-organic frameworks in oral drug delivery
    Aun Raza
    Wei Wu
    Asian Journal of Pharmaceutical Sciences, 2024, 19 (05) : 3 - 29
  • [6] Metal-organic frameworks for advanced drug delivery
    He, Siyu
    Wu, Li
    Li, Xue
    Sun, Hongyu
    Xiong, Ting
    Liu, Jie
    Huang, Chengxi
    Xu, Huipeng
    Sun, Huimin
    Chen, Weidong
    Gref, Ruxandra
    Zhang, Jiwen
    ACTA PHARMACEUTICA SINICA B, 2021, 11 (08) : 2362 - 2395
  • [7] Metal-organic frameworks for advanced drug delivery
    Siyu He
    Li Wu
    Xue Li
    Hongyu Sun
    Ting Xiong
    Jie Liu
    Chengxi Huang
    Huipeng Xu
    Huimin Sun
    Weidong Chen
    Ruxandra Gref
    Jiwen Zhang
    Acta Pharmaceutica Sinica B, 2021, 11 (08) : 2362 - 2395
  • [8] Metal-organic frameworks in oral drug delivery
    Raza, Aun
    Wu, Wei
    ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2024, 19 (05)
  • [9] Amorphous metal-organic frameworks for drug delivery
    Orellana-Tavra, Claudia
    Baxter, Emma F.
    Tian, Tian
    Bennett, Thomas D.
    Slater, Nigel K. H.
    Cheetham, Anthony K.
    Fairen-Jimenez, David
    CHEMICAL COMMUNICATIONS, 2015, 51 (73) : 13878 - 13881
  • [10] Metal organic frameworks as a drug delivery system for flurbiprofen
    AL Haydar, Muder
    Abid, Hussein Rasool
    Sunderland, Bruce
    Wang, Shaobin
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 2685 - 2695